Aktis Oncology (NASDAQ:AKTS) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Aktis Oncology (NASDAQ:AKTS) to a hold rating in a report issued on Saturday.

Aktis Oncology Stock Down 3.9%

Shares of NASDAQ AKTS opened at $19.75 on Friday. Aktis Oncology has a 52 week low of $19.02 and a 52 week high of $29.16.

Insiders Place Their Bets

In related news, major shareholder Bioventures 2018 L.P. Mpm purchased 1,112,777 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the acquisition, the insider owned 10,260,064 shares in the company, valued at $184,681,152. This trade represents a 12.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ecor1 Capital, Llc acquired 2,222,222 shares of the stock in a transaction on Monday, January 12th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $39,999,996.00. Following the purchase, the director directly owned 4,348,658 shares of the company’s stock, valued at $78,275,844. The trade was a 104.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 6,117,776 shares of company stock valued at $110,119,968. Insiders own 3.30% of the company’s stock.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.